Promoted Content
Promoted Content

Find Neurology Drugs in Phase I Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PF-05251749

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $710.0 million Upfront Cash: $75.0 million

            Deal Type: Acquisition January 13, 2020

            Details:

            With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.

            Virtual BoothOur shared vision is to have a World, free of Pain.

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 16, 2020

            Details:

            The Phase I trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of an investigational peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist following single and multiple-ascending doses.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HTL0018318

            Therapeutic Area: Neurology Product Name: HTL0018318

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Allergan Plc

            Deal Size: $3,290.0 million Upfront Cash: $125.0 million

            Deal Type: Terminated January 05, 2021

            Details:

            AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the partnership.